Fig. 2.

Clinical course of the patient, including changes in left ventricular mass index and ERT antibodies over time. IMT Immunomodulation therapy, – R Rituximab stopped, – IVIG immunoglobulins stopped, – M Methotrexate stopped, PD Pompe disease, IAR Infusion-associated reaction, ERT Enzyme replacement therapy with alglucosidase alfa